The Deadly Business of an Unregulated Global Stem Cell Industry

Lysaght, T; Lipworth, W; Hendl, T; Kerridge, I; Munsie, M; Waldby, C; Stewart, C

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Lysaght, T
dc.contributor.author	Lipworth, W
dc.contributor.author	Hendl, T
dc.contributor.author	Kerridge, I
dc.contributor.author	Munsie, M
dc.contributor.author	Waldby, C
dc.contributor.author	Stewart, C
dc.date.accessioned	2017-03-31
dc.date.available	2017-03-31
dc.date.issued	2017-03-29
dc.identifier.citation	Lysaght, T., Lipworth, W., Hendl, T., Kerridge I., Munsie, M., Waldby, C.,Stewart, C., The Deadly Business of an Unregulated Global Stem Cell Industry, Journal of Medical Ethics, Published online 29 March 2017. doi: 10.1136/medethics-2016-104046	en_AU
dc.identifier.uri	http://hdl.handle.net/2123/16573
dc.description.abstract	In 2016, the Office of the State Coroner of New South Wales released its report into the death of an Australian woman, Sheila Drysdale, who had died from complications of an autologous stem cell procedure at a Sydney clinic. In this report, we argue that Mrs Drysdale's death was avoidable, and it was the result of a pernicious global problem of an industry exploiting regulatory systems to sell unproven and unjustified interventions with stem cells.	en_AU
dc.description.sponsorship	Research for this paper was supported with the funding from an Australian Research Council Linkage Project Grant (LP150100739) and the National University of Singapore, Office of the Deputy President (Research and Technology)—Humanities and Social Sciences Research Fund (WBS: R-171-000-055-646).	en_AU
dc.language.iso	en	en_AU
dc.publisher	BMJ Publishing Group	en_AU
dc.subject	autologous stem cell	en_AU
dc.subject	stem cell regulation	en_AU
dc.subject	stem cell interventions	en_AU
dc.subject	autologous stem cell procedures	en_AU
dc.title	The Deadly Business of an Unregulated Global Stem Cell Industry	en_AU
dc.type	Article	en_AU
dc.type.pubtype	Post-print	en_AU